NWO TTW Perspectief round 2017/2018
The new NWO TTW Perspectief round for 2017/2018 will open on 2 October 2017. The guidelines for the new round of Perspectief will be similar to the 2016/2017 guidelines.
- NWO-TTW will open the Perspectief 2017/2018 for all 9 Topsectors – Life Sciences & Health, Agri&Food, Chemistry, High Tech Systems & Materials, Creative Industry, Energy, Horticulture & starting materials, Logistics and Water.
- The minimum contribution from NWO-TTW for the program budget is 1,5 million Euros. The maximum contribution from NWO-TTW is 4 million Euros.
- The co-financing demand for users is the same as in 2016/2017. The co-financing will need to be for the entire program and not on a project level. The program co-financing should consist of a cash contribution of at least 15% of the total budget. Next to this a contribution of 30% of the total program budget should consist of co-financing by users in cash and or in kind contribution.
- NWO-TTW offers project partners the option to agree on their own terms for IP distribution.
The Perspectief procedure has three phases:
- Phase 1: Announcement project initiative
Deadline: 2 November, 14:00 hrs
- Phase 2: Project design
Deadline: 7 December 2017, 14:00 hrs
- Phase 3: Final project proposal
Deadline: 14 May 2018, 14:00 hrs
Read more at http://www.stw.nl/nl/perspectief
Partnering with AMR Centre (United Kingdom)
The AMR Centre’s mission is to accelerate the development of new antimicrobial drugs and diagnostics. As such the AMR Centre works globally with companies and research institutions to support the development of their products from lead optimization through to proof of concept and beyond. The AMR Centre aims to progress circa 5 new projects each year. Read more at http://www.amrcentre.com/partnering/
NADP will engage with EU and global initiatives in order to achieve synergies and focus on strategic priorities These include among others :
- A new EU strategy on AMR, plus the ongoing work under the IMI Innovative Medicines Initiative
- G7/G20 initiative on combatting AMR
- World Economic Forum: “Antibiotic resistance is the next great global challenge – we must act now”
- The creation of CARB-X was prioritized in the 2015 US National Action Plan on Combating Antibiotic-Resistant Bacteria (CARB), which called for a biopharmaceutical accelerator to spur pre-clinical product development.
- The Global Antibiotic Research and Development Partnership (GARDP) was established in May 2016 as a joint initiative by the World Health Organization (WHO) and the Drugs for Neglected Diseases initiative (DNDi).
- WHO Global action plan on AMR, including prioritisation of pathogens
- WHO review of the antibiotics chapter of the WHO Essential Medicines list